Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of eleclazine and its metabolite, GS-623134, in participants with normal and impaired renal function. Participants in the healthy control group will be matched to participants with impaired renal function by age (± 5 years), gender, and body mass index (± 10%).

Timeline

Start

2015-05

Primary completion

2015-12

Completion

2015-12

Drugs

Indications